A detailed history of Abrdn PLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Abrdn PLC holds 43,054 shares of KRYS stock, worth $8.48 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
43,054
Previous 43,372 0.73%
Holding current value
$8.48 Million
Previous $7.96 Million 1.7%
% of portfolio
0.01%
Previous 0.02%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$174.7 - $213.66 $55,554 - $67,943
-318 Reduced 0.73%
43,054 $7.83 Million
Q2 2024

Aug 09, 2024

BUY
$153.12 - $183.64 $665,765 - $798,466
4,348 Added 11.14%
43,372 $7.96 Million
Q1 2024

May 08, 2024

BUY
$108.01 - $179.35 $4.21 Million - $7 Million
39,024 New
39,024 $6.94 Million

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $5.05B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.